|
Market Closed -
Nasdaq
16:00:00 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 4.230 USD | +3.93% |
|
+3.68% | -34.52% |
Company Valuation: Aquestive Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 156.2 | 48.85 | 134.9 | 324.6 | 788.1 | 530.9 | - | - |
| Change | - | -68.73% | 176.07% | 140.67% | 142.81% | -32.64% | - | - |
| Enterprise Value (EV) 1 | 179.8 | 73.73 | 138.5 | 285.6 | 704.5 | 452.9 | 530.9 | 530.9 |
| Change | - | -58.99% | 87.89% | 106.15% | 146.69% | -35.71% | 17.22% | 0% |
| P/E | -2.1x | -0.81x | -15.5x | -6.98x | -8.28x | -8.4x | -8.81x | -9x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 0.2x | -0x | -0.2x | 0.2x | 1.87x | 4.32x |
| Capitalization / Revenue | 3.07x | 1.02x | 2.67x | 5.64x | 17.7x | 10.4x | 7.83x | 4.98x |
| EV / Revenue | 3.54x | 1.55x | 2.74x | 4.96x | 15.8x | 8.87x | 7.83x | 4.98x |
| EV / EBITDA | -5.67x | -2.09x | -12x | -12.4x | -11.2x | -15.7x | -13.8x | -71.7x |
| EV / EBIT | -5.18x | -1.75x | -9.17x | -9.28x | -9.92x | -11.9x | -9.3x | -12.1x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.85 | -1.12 | -0.13 | -0.51 | -0.78 | -0.5038 | -0.48 | -0.47 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 50.83 | 47.68 | 50.58 | 57.56 | 44.54 | 51.04 | 67.77 | 106.7 |
| EBITDA 1 | -31.72 | -35.3 | -11.56 | -22.95 | -62.88 | -28.78 | -38.41 | -7.4 |
| EBIT 1 | -34.68 | -42.07 | -15.1 | -30.77 | -71.05 | -38.19 | -57.06 | -43.97 |
| Net income 1 | -70.54 | -54.41 | -7.87 | -44.14 | -83.78 | -62.87 | -60.23 | -62.8 |
| Net Debt 1 | 23.53 | 24.88 | 3.658 | -39.02 | -83.66 | -78 | - | - |
| Reference price 2 | 3.890 | 0.902 | 2.020 | 3.560 | 6.460 | 4.230 | 4.230 | 4.230 |
| Nbr of stocks (in thousands) | 40,164 | 54,156 | 66,767 | 91,178 | 122,003 | 125,512 | - | - |
| Announcement Date | 3/8/22 | 3/7/23 | 3/5/24 | 3/5/25 | 3/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.08x | 8.48x | -15.04x | - | 511M | |
| 37.66x | 13.18x | 27.98x | 0.53% | 1,143B | |
| 39.33x | 6.61x | 18.6x | 1.99% | 647B | |
| 37.45x | 8.4x | 17.37x | 2.4% | 506B | |
| 21.46x | 5.22x | 12.98x | 2.51% | 384B | |
| 103.38x | 5.8x | 24.86x | 2.4% | 350B | |
| 21.99x | 5.69x | 13.69x | 2.94% | 293B | |
| 22.31x | 4.51x | 12.87x | 1.96% | 265B | |
| 28.42x | 7.28x | 13.03x | 2.25% | 242B | |
| -45.78x | 7.1x | 27.53x | 2.07% | 197B | |
| Average | 25.81x | 7.23x | 15.39x | 2.12% | 402.8B | |
| Weighted average by Cap. | 35.27x | 8.35x | 20.48x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- AQST Stock
- Valuation Aquestive Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
